THR-123

THR-123 is an orally active ALK3 peptide agonist. THR-123 has a relatively weak binding to ALK2, but does not bind to ALK6. THR-123 suppresses inflammation, apoptosis and the epithelial-to-mesenchymal transition program and reverses established fibrosis in five mouse models of acute and chronic renal injury. THR-123 can be used for the study of kidney fibrosis[1].

Product Specifications

UNSPSC

12352209

Target

Apoptosis; Cadherin; Integrin; Interleukin Related; TGF-β Receptor

Related Pathways

Apoptosis; Cytoskeleton; Immunology/Inflammation; TGF-beta/Smad

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Smiles

O=C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CC(N)=O)C(N[C@@H](C(C)C)C(N[C@H]3CC(C)C)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CSSC[C@@H](C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC4=CC=C(C=C4)O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)NC3=O)N